Filing Details

Accession Number:
0001209191-22-017318
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-08 19:35:30
Reporting Period:
2022-03-04
Accepted Time:
2022-03-08 19:35:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582313 Xenon Pharmaceuticals Inc. XENE Pharmaceutical Preparations (2834) 980661854
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1619962 Sherrington Robin 200 - 3650 Gilmore Way
Burnaby A1 V5G 4W8
Evp, Strategy & Innovation No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2022-03-04 1,234 $3.67 33,466 No 4 M Direct
Common Shares Disposition 2022-03-04 696 $31.42 32,770 No 4 F Direct
Common Shares Acquisiton 2022-03-04 6,172 $3.67 38,942 No 4 M Direct
Common Shares Disposition 2022-03-04 6,710 $30.56 32,232 No 4 S Direct
Common Shares Disposition 2022-03-04 5,000 $30.15 27,232 No 4 S Direct
Common Shares Disposition 2022-03-04 5,000 $31.05 22,232 No 4 S Direct
Common Shares Disposition 2022-03-04 5,000 $30.23 17,232 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2022-03-04 1,234 $0.00 1,234 $3.67
Common Shares Stock Option (Right to Buy) Disposition 2022-03-04 6,172 $0.00 6,172 $3.67
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-03-10 No 4 M Direct
0 2022-03-10 No 4 M Direct
Footnotes
  1. The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
  2. Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
  3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  5. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  6. 1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years.
  7. Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.
  8. 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date